SIG
CRNX icon

Senator Investment Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Senator Investment Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-135,000
Closed -$6.9M – 72
2024
Q3 		$6.9M Hold
135,000
– – 0.33% 54
2024
Q2 		$6.05M Buy
+135,000
New +$6.23M 0.29% 53

Other funds holding CRNX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Senator Investment Group's CRNX Position: Q4 2024 in Review

Senator Investment Group sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2024, closing a stake of 135,000 shares — an estimated $6.9M sold.

Senator Investment Group first reported a position in CRNX in Q2 2024 and held it in 2 quarters. The position peaked at $6.9M in Q3 2024. 247 funds tracked by Wall St. Rank hold CRNX as of Q4 2024.

  • Senator Investment Group reported no remaining Crinetics Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Senator Investment Group sold 135,000 Crinetics Pharmaceuticals shares in Q4 2024, an estimated $6.9M.
  • Senator Investment Group first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Senator Investment Group's Crinetics Pharmaceuticals position peaked at $6.9M in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2024.

Based on Senator Investment Group's 13F filing for Q4 2024, filed 13 Feb 2025.